Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 2
2017 1
2018 3
2019 5
2020 17
2021 9
Text availability
Article attribute
Article type
Publication date

Search Results

33 results
Results by year
Filters applied: . Clear all
Page 1
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.
Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Turka A, Lam LP, Morgan RA, Friedman K, Massaro M, Wang J, Russotti G, Yang Z, Campbell T, Hege K, Petrocca F, Quigley MT, Munshi N, Kochenderfer JN. Raje N, et al. Among authors: madduri d. N Engl J Med. 2019 May 2;380(18):1726-1737. doi: 10.1056/NEJMoa1817226. N Engl J Med. 2019. PMID: 31042825 Free PMC article. Clinical Trial.
An inflammatory cytokine signature predicts COVID-19 severity and survival.
Del Valle DM, Kim-Schulze S, Huang HH, Beckmann ND, Nirenberg S, Wang B, Lavin Y, Swartz TH, Madduri D, Stock A, Marron TU, Xie H, Patel M, Tuballes K, Van Oekelen O, Rahman A, Kovatch P, Aberg JA, Schadt E, Jagannath S, Mazumdar M, Charney AW, Firpo-Betancourt A, Mendu DR, Jhang J, Reich D, Sigel K, Cordon-Cardo C, Feldmann M, Parekh S, Merad M, Gnjatic S. Del Valle DM, et al. Among authors: madduri d. Nat Med. 2020 Oct;26(10):1636-1643. doi: 10.1038/s41591-020-1051-9. Epub 2020 Aug 24. Nat Med. 2020. PMID: 32839624
Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma.
Perumal D, Imai N, Laganà A, Finnigan J, Melnekoff D, Leshchenko VV, Solovyov A, Madduri D, Chari A, Cho HJ, Dudley JT, Brody JD, Jagannath S, Greenbaum B, Gnjatic S, Bhardwaj N, Parekh S. Perumal D, et al. Among authors: madduri d. Clin Cancer Res. 2020 Jan 15;26(2):450-464. doi: 10.1158/1078-0432.CCR-19-2309. Epub 2019 Dec 19. Clin Cancer Res. 2020. PMID: 31857430 Free PMC article.
An inflammatory cytokine signature helps predict COVID-19 severity and death.
Del Valle DM, Kim-Schulze S, Hsin-Hui H, Beckmann ND, Nirenberg S, Wang B, Lavin Y, Swartz T, Madduri D, Stock A, Marron T, Xie H, Patel MK, van Oekelen O, Rahman A, Kovatch P, Aberg J, Schadt E, Jagannath S, Mazumdar M, Charney A, Firpo-Betancourt A, Mendu DR, Jhang J, Reich D, Sigel K, Cordon-Cardo C, Feldmann M, Parekh S, Merad M, Gnjatic S. Del Valle DM, et al. Among authors: madduri d. medRxiv. 2020 May 30:2020.05.28.20115758. doi: 10.1101/2020.05.28.20115758. Preprint. medRxiv. 2020. PMID: 32511562 Free PMC article. Updated.
COVID-19 infections and outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centers.
Hultcrantz M, Richter J, Rosenbaum C, Patel D, Smith E, Korde N, Lu S, Mailankody S, Shah U, Lesokhin A, Hassoun H, Tan C, Maura F, Derkacs A, Diamond B, Rossi A, Pearse RN, Madduri D, Chari A, Kaminetsky D, Braunstein M, Gordillo C, Davies F, Jagannath S, Niesvizky R, Lentzsch S, Morgan G, Landgren O. Hultcrantz M, et al. Among authors: madduri d. medRxiv. 2020 Jun 11:2020.06.09.20126516. doi: 10.1101/2020.06.09.20126516. Preprint. medRxiv. 2020. PMID: 32577667 Free PMC article. Updated.
Selinexor in relapsed/refractory multiple myeloma.
Richter J, Madduri D, Richard S, Chari A. Richter J, et al. Among authors: madduri d. Ther Adv Hematol. 2020 Jun 9;11:2040620720930629. doi: 10.1177/2040620720930629. eCollection 2020. Ther Adv Hematol. 2020. PMID: 32566115 Free PMC article. Review.
Myeloma CAR-T CRS Management With IL-1R Antagonist Anakinra.
Jatiani SS, Aleman A, Madduri D, Chari A, Cho HJ, Richard S, Richter J, Brody J, Jagannath S, Parekh S. Jatiani SS, et al. Among authors: madduri d. Clin Lymphoma Myeloma Leuk. 2020 Sep;20(9):632-636.e1. doi: 10.1016/j.clml.2020.04.020. Epub 2020 May 11. Clin Lymphoma Myeloma Leuk. 2020. PMID: 32553791 No abstract available.
33 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page